Details for Patent: 10,456,396
✉ Email this page to a colleague
Which drugs does patent 10,456,396 protect, and when does it expire?
Patent 10,456,396 protects TYRVAYA and is included in one NDA.
This patent has thirty-eight patent family members in nineteen countries.
Summary for Patent: 10,456,396
| Title: | Dry eye treatments |
| Abstract: | Described herein are methods and pharmaceutical formulations for treating dry eye disease. |
| Inventor(s): | Ackermann, Jr.; Douglas Michael (Reno, NV), Loudin; James (Houston, TX), Mandell; Kenneth J. (Lexington, MA) |
| Assignee: | Oyster Point Pharma, Inc. (Princeton, NJ) |
| Application Number: | 15/422,382 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; Delivery; Device; |
Drugs Protected by US Patent 10,456,396
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oyster Point Pharma | TYRVAYA | varenicline tartrate | SPRAY;NASAL | 213978-001 | Oct 15, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED) | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,456,396
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015336216 | ⤷ Sign Up | |||
| Australia | 2020213351 | ⤷ Sign Up | |||
| Brazil | 112017008097 | ⤷ Sign Up | |||
| Brazil | 122022025737 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
